By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Verseon Corporation 

48820-100B Kato Road

Fremont  California  94538  U.S.A.
Phone: 510-225-9000 Fax: 510-225-9001


SEARCH JOBS


Industry
Biotechnology






Company News
Unique Mechanism Of Action Of Verseon (VSN.L)’s Novel Class Of Anticoagulants To Be Presented At American Chemical Society Meeting 3/30/2017 11:52:01 AM
Verseon (VSN.L) To Showcase Low Bleeding Risk Anticoagulation Candidates At BIO-Europe Spring 3/20/2017 9:40:09 AM
Verseon (VSN.L) Granted U.S. Patents Covering Its Novel Serine Protease Inhibitors 1/4/2017 9:01:12 AM
Further Research Confirms That Verseon (VSN.L)’s New Class Of Anticoagulants Reduce Bleeding Risk Compared To NOACs By Preserving Platelet Function 12/8/2016 12:58:09 PM
Further Research Confirms That Verseon (VSN.L)’s New Class Of Anticoagulants Reduce Bleeding Risk Compared To NOACs By Preserving Platelet Function 12/7/2016 11:14:03 AM
Research To Be Presented At ASH Annual Meeting Shows Verseon (VSN.L)’s New Class Of Anticoagulants Prevents Thrombosis While Preserving Platelet Function 11/28/2016 9:08:35 AM
BIO2016: Verseon (VSN.L) Reveals More Details On Its Family Of Anti-Coagulants At BIO 2016 International Convention 6/6/2016 2:43:23 PM
Verseon (VSN.L) Presents Further Trial Data On The Low Bleeding Risk Of Its Family Of Preclinical Anti-Coagulant Drugs At BioEurope Conference 4/11/2016 10:53:44 AM
Verseon (VSN.L) Final Results And Good Progress On New Family Of Anti-Coagulants 3/9/2016 10:02:52 AM
Verseon (VSN.L) To Unveil New Preclinical Results For Novel Class Of Oral Anticoagulants At The 3rd International Conference On Heart & Brain 2/10/2016 9:41:23 AM
12
//-->